Projects per year
Personal profile
Biography
Associate Professor Cornelia Landersdorfer leads the Antimicrobial Pharmacokinetics, Pharmacodynamics and Dosage regimen optimisation research group at the Monash Institute of Pharmaceutical Sciences. She obtained her PhD in Pharmaceutical Sciences from the University of Wuerzburg (2006), completed postdoctoral studies in PK/PD modelling at the State University of New York (SUNY), and worked as a Scientist at Ordway Research Institute & the Institute for Clinical Pharmacodynamics (ICPD), NY. In 2011 she joined MIPS. She has since been awarded an NHMRC Career Development Fellowship and the ASCEPT Denis Wade J&J New Investigator Award. In 2018, Cornelia received the prestigious Georgina Sweet Award for Women in Quantitative Biomedical Science. In 2020 she was awarded the Faculty of Pharmacy and Pharmaceutical Sciences Research Impact award. She has led and is leading NHMRC Project and Ideas grants and is the Project Director of a large NIH clinical PK modelling contract.Associate Professor - Centre for Medicine Use and Safety.
In 2020, Cornelia joined the Monash Center to Impact AMR as a founding member and provides expert advice to our Research and Industry Strategy, Clinical Evaluation, and Training and Inclusion workkng groups.
Related Links:
Research interests
Antibiotic mono- and combination therapy to achieve synergistic bacterial killing and prevent resistance
Population pharmacokinetics, pharmacodynamics, and optimised dosage regimens of anti-infectives and other agents
Mechanism-based mathematical modelling
Tissue penetration into bone and other tissues
Mechanism-based population modelling of the glucose-insulin system, drug effects and disease progression in type 2 diabetes
Renal elimination mechanisms
Monash teaching commitment
BPS2041 Drug delivery and pharmacokinetics (second year Pharm Sci) - Unit coordinator and teaching pharmacokinetics
BPS3332 Applied pharmacokinetics/pharmacodynamics (third year Pharm Sci) - Unit coordinator and teaching pharmacokinetics/pharmacodynamics
Coordinating the CMUS PhD student training (CMUS HDR modules)
PHR1022 How Medicines Work II (first year Pharmacy) - teaching pharmacokinetics, pharmacogenomics, pharmacokinetics/pharmacodynamics
PhD student training in workshops on mechanism-based, population pharmacokinetic / pharmacodynamic modelling and simulation
Teaching applications of mechanism-based modelling to pharmaceutical industry
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Pharmaceutical Sciences, PhD, Modern pharmacokinetic / pharmacodynamic techniques to study physiological mechanisms of pharmacokinetic drug-drug interactions and disposition of antibiotics and to assess clinical relevance, Julius-Maximilians-Universität Würzburg (University of Wurzburg)
2002 → 2006
Award Date: 26 Sept 2006
Pharmacy and Pharmaceutical Sciences, BPharm, Universitat Regensburg (University of Regensburg)
1996 → 2001
External positions
Adjunct Associate Professor, University at Buffalo, State University of New York
15 Aug 2009 → …
Research area keywords
- Pharmacokinetics
- Pharmacodynamics
- Antimicrobial resistance
- Mathematical modelling
- Pharmacokinetics and Pharmacodynamics of Antibiotics
- Pseudomonas aeruginosa
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
EARSHOT: An international, multicentre prospective cohort study evaluating the risk of hearing loss in children receiving antibiotic treatment
Gwee, A. (Primary Chief Investigator (PCI)), Snelling, T. (Chief Investigator (CI)), Christodoulou, J. (Chief Investigator (CI)), Landersdorfer, C. (Chief Investigator (CI)), Conyers, R. (Chief Investigator (CI)), Donath, S. M. (Chief Investigator (CI)), Norman, R. (Chief Investigator (CI)), Messina, N. (Chief Investigator (CI)), Shanthikumar, S. (Chief Investigator (CI)) & Carew, P. (Chief Investigator (CI))
1/07/25 → 30/06/30
Project: Research
-
PHASEK: Phage-Antimicrobial combination Strategies for management of multidrug-resistant E. coli and K. pneumoniae
Abbott, I. (Primary Chief Investigator (PCI)), Peleg, A. (Chief Investigator (CI)), Landersdorfer, C. (Chief Investigator (CI)), Starkey, M. (Chief Investigator (CI)) & Gordillo Altamirano, F. (Chief Investigator (CI))
1/04/25 → 30/03/28
Project: Research
-
Overcoming resistance emergence to recent antibiotics by a multi-omics informed quantitative and systems pharmacology approach
Landersdorfer, C. (Primary Chief Investigator (PCI)), Oliver, A. (Chief Investigator (CI)), Harper, M. (Chief Investigator (CI)), Boyce, J. (Associate Investigator (AI)) & Peleg, A. (Associate Investigator (AI))
1/01/25 → 31/12/28
Project: Research
-
Harnessing type VI secretion system lysins for fighting bacterial superbugs
Boyce, J. (Primary Chief Investigator (PCI)), Harper, M. (Chief Investigator (CI)), Roper, D. (Chief Investigator (CI)), Landersdorfer, C. (Associate Investigator (AI)), Peleg, A. (Associate Investigator (AI)) & Vollmer, W. (Associate Investigator (AI))
1/01/25 → 31/12/27
Project: Research
-
Bridging the gap between urinary tract infection pharmacokinetic/pharmacodynamic in vitro models and the optimization of antibiotic selection, dosing strategies, clinical breakpoints, and novel drug development
Abbott, I. (Primary Chief Investigator (PCI)), Peleg, A. (Chief Investigator (CI)), Landersdorfer, C. (Associate Investigator (AI)), Bradshaw, C. (Associate Investigator (AI)), Meletiadis, J. (Associate Investigator (AI)), Huttner, A. (Associate Investigator (AI)) & Patel, R. (Associate Investigator (AI))
United States Food and Drug Administration
29/09/23 → 28/09/26
Project: Research
-
Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions
Kostoulias, X., Fu, Y., Morris, F. C., Yu, C., Qu, Y., Chang, C. C., Blakeway, L., Landersdorfer, C. B., Abbott, I. J., Wang, L., Wisniewski, J., Yu, Y., Li, J. & Peleg, A. Y., Feb 2025, In: Journal of Antimicrobial Chemotherapy. 80, 2, p. 372-380 9 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
Cholesterol-terminated cationic lipidated oligomers (CLOs) as a new class of antifungals
Mahboob, M. B. H., Subramaniam, S., Tait, J. R., Grace, J. L., Elliott, A. G., Floyd, H., Zuegg, J., Quinn, J. F., Prestidge, C. A., Landersdorfer, C. B. & Whittaker, M. R., 28 Feb 2025, In: Journal of Materials Chemistry B. 13, 8, p. 2776-2795 20 p.Research output: Contribution to journal › Article › Research › peer-review
-
Clinical and Quantitative Pharmacology Considerations of mRNA Therapeutics and Vaccine Development: Bridging Translational and Platform Gaps for Enhanced Decision Making
Van, L., Chen, N., Miyazawa, K., Zhang, M., Landersdorfer, C. B., Kirkpatrick, C. M. J., Pennucci, J., Finn, P. F., Ward, C. & Gao, W., Dec 2025, In: Clinical Pharmacology & Therapeutics. 118, 6, p. 1297-1312 16 p.Research output: Contribution to journal › Review Article › Research › peer-review
1 Citation (Scopus) -
Current and future options for the treatment of serious infections due to carbapenem-resistant Pseudomonas aeruginosa
Horcajada, J. P., Gales, A. C., Isler, B., Kaye, K., Kwa, A., Landersdorfer, C. B., Montero, M. M., Oliver, A., Pogue, J., Shields, R., Villegas, M. V., Yahav, D. & Paterson, D. L., 9 Oct 2025, (Accepted/In press) In: Clinical Microbiology Reviews. 37 p.Research output: Contribution to journal › Review Article › Research › peer-review
-
Cyclic and linear cationic polymers based on metathesis polymerization for antibacterial and antifungal Applications
Gonnot, C., Hassan Mahboob, M. B., Aumond, M., Tait, J. R., Nay, K., Nazemi, K., Floyd, H., Zuegg, J., Boeda, F., Landersdorfer, C. B., Quinn, J. F., Fontaine, L., Whittaker, M. R. & Montembault, V., 21 Apr 2025, In: European Polymer Journal. 230, 7 p., 113875.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus)
Prizes
-
ASCEPT Denis Wade J&J New Investigator Award
Landersdorfer, C. (Recipient), 2013
Prize: Prize (including medals and awards)
-
Future Research Leader Award, Faculty of Pharmacy and Pharmaceutical Sciences
Landersdorfer, C. (Recipient), 2016
Prize: Prize (including medals and awards)
-
Georgina Sweet Award for Women in Quantitative Biomedical Science
Landersdorfer, C. (Recipient), 8 Oct 2018
Prize: Prize (including medals and awards)
-
Research Impact Award, Faculty of Pharmacy and Pharmaceutical Sciences
Landersdorfer, C. (Recipient), 2020
Prize: Prize (including medals and awards)
Activities
-
30th European Congress of Clinical Microbiology & Infectious Diseases
Landersdorfer, C. (Invited speaker)
Apr 2020 → …Activity: Participating in or organising an event types › Contribution to conference
-
Co-chair ASCEPT Drug Disposition and Response Special Interest Group
Landersdorfer, C. (Chair/ Co-Chair)
Nov 2019 → …Activity: External Academic Engagement › Professional association or peak discipline body
-
Antimicrobial Agents and Chemotherapy (Journal)
Landersdorfer, C. (Editorial board member)
1 Jan 2019 → 31 Dec 2021Activity: Publication peer-review and editorial work types › Editorial responsibility
-
ASCEPT-PAGANZ conference
Landersdorfer, C. (Session chair)
25 Nov 2019Activity: Participating in or organising an event types › Contribution to conference
-
Australian Society for Antimicrobials Research Grant Reviewer
Landersdorfer, C. (Reviewer)
2018 → …Activity: External Academic Engagement › Grant review responsibilities
Press/Media
-
Radio interview on being a recipient of the Georgina Sweet Award for Women in Quantitative Biomedical Science
21/10/18
1 item of Media coverage
Press/Media: Profile/Interview
-
Interview for documentary on superbugs - a different lens
25/05/18
1 item of Media coverage
Press/Media: Profile/Interview
-